Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
Benzinga Newsdesk 2 months ago
News
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to
- NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine
- Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package
- Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan